GLI1 and acute promyelocytic leukemia: Arsenic trioxide, a Gli inhibitor approved by the FDA for the treatment of acute promyelocytic leukemia, binds directly to Gli1 and Gli2, among other actions, causing the inhibition of their activity (205, 206).